Patents by Inventor Madeline M. Butler

Madeline M. Butler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY
    Publication number: 20140357856
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 4, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
    Patent number: 8791083
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 29, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Antisense modulation of PTP1B expression
    Patent number: 8017760
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: September 13, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madeline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
  • CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY
    Publication number: 20090258931
    Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.
    Type: Application
    Filed: February 19, 2009
    Publication date: October 15, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
  • Antisense modulation of PTP1B expression
    Patent number: 7563884
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: July 21, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline R. Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Antisense Oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
    Publication number: 20040152652
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr; (TNF-&agr;). Antisense oligonucleotides targeted to nucleic acids encoding TNF-&agr; are preferred. Methods of using these oligonucleotides for inhibition of TNF-&agr; expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-&agr; are provided.
    Type: Application
    Filed: August 26, 2003
    Publication date: August 5, 2004
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan
  • Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
    Publication number: 20040142346
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr; (TNF-&agr;). Antisense oligonucleotides targeted to nucleic acids encoding TNF-&agr; are preferred. Methods of using these oligonucleotides for inhibition of TNF-&agr; expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-&agr; are provided.
    Type: Application
    Filed: August 29, 2003
    Publication date: July 22, 2004
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan
  • Antisense modulation of PI3K P85 Expression
    Publication number: 20040077580
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 22, 2004
    Inventors: Brett P. Monia, Lex M. Cowsert, Susan Murray, Madeline M. Butler, Nicholas M. Dean
  • Antisense modulation of PTP1B expression
    Publication number: 20030220282
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: February 7, 2003
    Publication date: November 27, 2003
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madeline M. Butler, Robert McKay, Susan M. Freier
  • Antisense modulation of glycogen synthase kinase3 alpha expression
    Publication number: 20030216333
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 alpha. Methods of using these compounds for modulation of glycogen synthase kinase 3 alpha expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 alpha are provided.
    Type: Application
    Filed: November 4, 2002
    Publication date: November 20, 2003
    Inventors: Brett P Monia, Robert McKay, Madeline M Butler, Jacqueline Wyatt
  • Antisense modulation of glycogen synthase kinase 3 beta expression
    Publication number: 20030211608
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
    Type: Application
    Filed: November 4, 2002
    Publication date: November 13, 2003
    Inventors: Madeline M. Butler, Robert McKay, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of PTP1B expression
    Patent number: 6602857
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: August 5, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline Wyatt, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Methods for identifying compounds that inhibit or reduce PTP1B expression
    Publication number: 20030108883
    Abstract: The present invention relates to methods for identifying compounds that inhibit PTP1B mRNA and protein expression in insulin resistant non-human mammals.
    Type: Application
    Filed: February 12, 2002
    Publication date: June 12, 2003
    Inventors: Cristina M. Rondinone, James M. Trevillyan, Bradley A. Zinker, Jeffrey F. Waring, Mike Jirousek, Madeline M. Butler, Lex M. Cowsert, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of hormone-sensitive lipase expression
    Publication number: 20030096771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hormone-sensitive lipase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hormone-sensitive lipase. Methods of using these compounds for modulation of hormone-sensitive lipase expression and for treatment of diseases associated with expression of hormone-sensitive lipase are provided.
    Type: Application
    Filed: July 26, 2001
    Publication date: May 22, 2003
    Inventors: Madeline M. Butler, Andrew T. Watt, Susan M. Freier, Jacqueline Wyatt
  • Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
    Publication number: 20030022848
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr; (TNF-&agr;). Antisense oligonucleotides targeted to nucleic acids encoding TNF-&agr;_ are preferred. Methods of using these oligonucleotides for inhibition of TNF-&agr; expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-&agr; are provided.
    Type: Application
    Filed: April 2, 2001
    Publication date: January 30, 2003
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan
  • Antisense modulation of PTP1B expression
    Publication number: 20020055479
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 9, 2002
    Inventors: Lex M. Cowsert, Jacqueline Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Antisense modulation of glycogen synthase kinase 3 beta expression
    Patent number: 6323029
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: November 27, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Madeline M. Butler, Robert McKay, Brett P. Monia, Jacqueline Wyatt
  • Antisense inhibition of glycogen synthase kinase 3 alpha expression
    Patent number: 6316259
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 alpha. Methods of using these compounds for modulation of glycogen synthase kinase 3 alpha expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 alpha are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: November 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert McKay, Madeline M. Butler, Jacqueline Wyatt
  • Antisense inhibition of C/EBP alpha expression
    Patent number: 6306655
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP alpha. Methods of using these compounds for modulation of C/EBP alpha expression and for treatment of diseases associated with expression of C/EBP alpha are provided.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: October 23, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Jacqueline Wyatt
  • Antisense inhibition of C/EBP beta expression
    Patent number: 6271030
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP beta. Methods of using these compounds for modulation of C/EBP beta expression and for treatment of diseases associated with expression of C/EBP beta are provided.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Jacqueline Wyatt